Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Previous Hold Today AMGN ranks #3136 as HOLD CANDIDATE #3136 Next Hold

AMGN stock forecast Amgen Inc.

AMGN stock forecast

Amgen (AMGN) closed the most recent trading day at $184.08, moving +0.72% from the previous trading session.

Read more

The Zacks Analyst Blog Highlights: Amgen, Alexion, Regeneron, Allergan and Savara

Read more

The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands

Read more

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Read more

This is an excerpt from a story delivered exclusively to Business Insider Intelligence Digital Health Pro subscribers. To receive the full story plus other insights each morning, click here . France-based pharma giant Sanofi is teaming up with Google to use the tech giant's AI and cloud-computing tools in a new Innovation Lab, per Bio Space. The goal of the partnership is threefold: to speed up drug discovery, maximize operational flows, and improve the patient experience. Using AI to streamline complex and costly processes is a budding trend within the pharma industry. Pharma giants are rushing to get a hold of AI. Eli Lilly struck a $560 million deal with San Francisco-based AI developer Atomwise — which also holds partnerships with Merck and AbbVie — to accelerate drug discovery earlier this month, and AstraZeneca tied up with UK-based BenevolentAI in May. It makes sense for pharma companies to lean on tech that makes drug development more efficient: Drug makers shell out $2.6 billion to develop a new prescription medication and bring it to market, up from the $1 billion it cost in the early 2000s.

Read more

Top Analyst Reports for Broadcom, Amgen & NVIDIA

Read more

FDA OKs Amgen's Herceptin biosimilar
05:28pm, Thursday, 13'th Jun 2019
The FDA approves Amgen's ([[AMGN]] +0.4%) KANJINTI (trastuzumab-anns), its biosimilar to Roche's ([[RHHBY]] +0.4%) Herceptin (trastuzumab).

Read more

Amgen (AMGN) closed the most recent trading day at $175.60, moving +0.56% from the previous trading session.

Read more

Amgen Inc. (NASDAQ:AMGN) Investor Event at ASCO 2019 June 03, 2019 07:30 PM ET Company Participants Arvind Sood - Vice President of Investor Relations Marwan Fa

Read more

In the latest trading session, Amgen (AMGN) closed at $174.45, marking a -0.06% move from the previous day.

Read more

Amgen releases data from its phase 1 study on an investigational bispecific T cell engager molecules, updated with investigational AMG 420 results for the treatment of refractory multiple myeloma….AMGN

Read more

At ASCO, Amgen (AMGN) presented encouraging initial data set for AMG 510, its novel investigational KRAS inhibitor for solid tumor.

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Ascendis Pharma A/S (NASDAQ: ASND ) Mirati Therapeutics Inc (NASDAQ: MRTX )(reacted to ASCO presentation on a rival drug by Amgen, Inc. (NASDAQ: AMGN )) Misonix, Inc. (NASDAQ: MSON )(received FDA approval for its ultrasonic surgical platform) Trevi Therapeutics Inc (NASDAQ: TRVI ) (analyst began covering the stock after the IPO quiet period expiry ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 3) Arcus Biosciences Inc (NYSE: RCUS ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aduro BioTech Inc (NASDAQ: ADRO )(reacted to ASCO presentation on its Phase 1b data for ADU-S100) Akers Biosciences Inc (NASDAQ: AKER ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Celldex Therapeutics, Inc. (NASDAQ: CLDX )(reacted to ASCO presentation on CDX-3379) Cerus Corporation (NASDAQ: CERS ) ContraVir Pharmaceuticals (NASDAQ: CTRV )(began trading on a reverse split-adjusted basis) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CytRx Corporation (NASDAQ: CYTR ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd …

Read more

Shares of Amgen Inc. rose 4% Monday after the company announced that its investigational cancer drug shrank tumors in 50% of lung cancer patients who were…

Read more

Amgen Inc.'s (AMGN) charts are indicating a bounce in the biotech company's shares is possible, but that the stock is in a longer-term downtrend and likely is not finished declining….AMGN

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank